Evidence map›Paper›PMID 36217248›Full record

ArticleHistopathology2023

Prognosis of mucinous colon cancer is determined by histological biomarkers rather than microsatellite instability.

Peter H van Zwam, Elisa M Vink-Börger, Carolien M Bronkhorst, Adriaan P de Bruine, Anneke A van der Wurff, Harm J T Rutten, Valery E P P Lemmens, Iris D Nagtegaal, Niek Hugen

Open access · hybridAbstract read
In one paragraph

Article in Histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Peter H van ZwamDepartment of Pathology, Eurofins PAMM, Eindhoven.
Elisa M Vink-BörgerDepartment of Pathology, Radboud University Medical Center, Nijmegen.
Carolien M BronkhorstDepartment of Pathology, Jeroen Bosch Hospital, 's Hertogenbosch.
Adriaan P de BruineDepartment of Pathology, VieCuri Medical Centre, Venlo.
Anneke A van der WurffDepartment of Pathology, Elisabeth-Twee Steden Hospital, Tilburg.
Harm J T RuttenDepartment of Surgery, Catharina Hospital, Eindhoven.
Valery E P P LemmensNetherlands Comprehensive Cancer Organisation, Utrecht.
Iris D NagtegaalDepartment of Pathology, Radboud University Medical Center, Nijmegen.ORCID https://orcid.org/0000-0003-0887-4127
Niek HugenDepartment of Surgery, Radboud University Medical Center, Nijmegen.ORCID https://orcid.org/0000-0002-2157-1561
Radboud University Nijmegen · NLEurofins (Netherlands) · NLJeroen Bosch Ziekenhuis · NLNetherlands Comprehensive Cancer Organisation · NLSt. Elisabeth Hospital · CWVieCuri Medisch Centrum · NL

Funding

Dutch Maag Darm Lever Stichting (MLDS) FP 14-10
6 · The paper itself

Abstract

The prognostic value of microsatellite instability (MSI), as well as other histological characteristics such as lymphovascular invasion (LI), perineural invasion (PNI) and extramural vascular invasion (EMVI), is unclear in colorectal mucinous carcinoma (MC). This study aims to determine the relevance of these factors in MC patients and analyses the role of MSI in stage III MC patients treated with adjuvant chemotherapy. A cohort of 650 patients diagnosed with stages I-IV colonic MC from 2000 to 2010 was selected from PALGA, the nationwide Dutch pathology databank. Histopathology was revised and mismatch repair (MMR) status determined. Univariate and multivariate survival analyses were performed. Deficient MMR (dMMR) was found in 33% of MCs and correlated with female gender and right-sidedness, but also with lower tumour stage (stages I/II: 73.2 versus 47%; P < 0.0001) and the absence of EMVI (9.7 versus 23.7%; P < 0.0001) and PNI (5.6 versus 12.7%; P = 0.005). On univariate analysis OS was better for dMMR MC than for proficient MMR (pMMR) MC (median OS of 9.7 versus 5.0 years; P = 0.009), but MMR status was no longer a relevant prognostic factor on multivariate analysis [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.70-1.18]. Stage III MC patients benefited from adjuvant chemotherapy, and dMMR status was associated with better OS in this group (HR = 0.35, 95% CI = 0.13-0.94). EMVI, LI and PNI, but not MMR, status are independent prognostic factors for survival in MC patients. Stage III MC patients benefit from adjuvant chemotherapy and dMMR status is associated with improved survival when adjuvant chemotherapy is given.

Indexed as

Colonic NeoplasmsResearch DesignFemaleHumansPrognosisadjuvant chemotherapycolon cancermicrosatellite instabilitymismatch repair deficiencymucinous carcinoma

Identifiers

PMID36217248
PMCPMC10100398
OpenAlexW4304163519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.